MaxCyte, Inc. (MXCT)
NASDAQ: MXCT · Real-Time Price · USD
1.230
+0.020 (1.65%)
At close: Jan 21, 2026, 4:00 PM EST
1.250
+0.020 (1.63%)
After-hours: Jan 21, 2026, 5:36 PM EST
MaxCyte Employees
MaxCyte had 114 employees as of December 31, 2024. The number of employees decreased by 29 or -20.28% compared to the previous year.
Employees
114
Change (1Y)
-29
Growth (1Y)
-20.28%
Revenue / Employee
$301,921
Profits / Employee
-$400,272
Market Cap
131.21M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 114 | -29 | -20.28% |
| Dec 31, 2023 | 143 | 18 | 14.40% |
| Dec 31, 2022 | 125 | 41 | 48.81% |
| Dec 31, 2021 | 84 | 19 | 29.23% |
| Dec 31, 2019 | 65 | 33 | 103.13% |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Inogen | 766 |
| Neuronetics | 716 |
| Treace Medical Concepts | 477 |
| AVITA Medical | 260 |
| Apyx Medical | 220 |
| CVRx, Inc. | 206 |
| LENSAR | 140 |
| Hyperfine | 111 |
MXCT News
- 9 days ago - MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Financial Results - GlobeNewsWire
- 7 weeks ago - Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPO - Business Wire
- 2 months ago - MaxCyte, Inc. (MXCT) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - MaxCyte Announces Planned CFO Transition in 2026 - GlobeNewsWire
- 2 months ago - MaxCyte Reports Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance - GlobeNewsWire
- 2 months ago - MaxCyte Reports Preliminary Third Quarter 2025 Financial Results and Reiterates Full Year 2025 Revenue Guidance - GlobeNewsWire
- 3 months ago - MaxCyte to Report Third Quarter 2025 Financial Results on November 5, 2025 - GlobeNewsWire
- 3 months ago - MaxCyte Announces Strategic Platform License Agreement with Moonlight Bio to Advance T Cell Therapies for Solid Tumors - GlobeNewsWire